Logo

GLSI

Greenwich LifeSciences, Inc.

GLSI

Greenwich LifeSciences, Inc. • NASDAQ
$8.73 ▲ 4.55% (+0.38)
Market Cap $120.85 M
52w High $15.47
52w Low $7.78
Dividend Yield 0%
P/E -5.98
Volume 35.70K
Outstanding Shares 13.84M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $4.175M ▲ $-4.152M ▼ 0% $-0.3 $-4.152M ▼
Q2-2025 $0 $4.046M ▲ $-4.025M ▼ 0% $-0.3 ▼ $-4.045M ▼
Q1-2025 $0 $3.282M ▼ $-3.258M ▲ 0% $-0.25 ▲ $-3.281M ▲
Q4-2024 $0 $8.083M ▲ $-8.04M ▼ 0% $-0.61 ▼ $-8.039M ▼
Q3-2024 $0 $2.729M $-2.669M 0% $-0.2 $-2.728M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $3.807M ▲ $3.807M ▲ $1.622M ▼ $2.185M ▲
Q2-2025 $3.125M ▲ $3.125M ▲ $1.686M ▲ $1.439M ▲
Q1-2025 $2.75M ▼ $2.751M ▼ $1.439M ▼ $1.312M ▼
Q4-2024 $4.092M ▼ $4.094M ▼ $1.56M ▲ $2.534M ▼
Q3-2024 $5.822M $5.825M $842.384K $4.983M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-4.152M ▼ $-2.671M ▼ $0 $3.353M ▲ $681.877K ▲ $-2.671M ▼
Q2-2025 $-4.025M ▼ $-2.233M ▼ $0 $2.608M ▲ $375.142K ▲ $-2.233M ▼
Q1-2025 $-3.258M ▲ $-1.834M ▲ $0 $492.423K ▲ $-1.342M ▲ $-1.834M ▲
Q4-2024 $-8.04M ▼ $-1.852M ▲ $0 $121.829K ▼ $-1.73M ▼ $-1.852M ▲
Q3-2024 $-2.669M $-2.584M $0 $1.181M $-1.403M $-2.584M

Five-Year Company Overview

Income Statement

Income Statement Income Statement: Greenwich LifeSciences is still a pure research-stage biotech company, so it has no product sales yet. Its income statement is driven almost entirely by research and development and overhead costs, which translate into ongoing annual losses. These losses have been gradually widening on a per‑share basis as the company advances its clinical programs and covers public-company costs. This pattern is typical for a small clinical-stage biotech: spending first to build the data and regulatory package, with no offsetting revenue until and unless a drug is approved and commercialized. The key point is that the business today is an R&D effort rather than an operating commercial company.

Balance Sheet

Balance Sheet Balance Sheet: The company’s balance sheet appears very light, with historically modest cash and equity and no financial debt. The absence of debt reduces financial pressure from interest or required repayments, but it also means the company must rely on equity raises or other funding sources to finance its trials. The most recent figures suggest that reported cash and total assets are close to depleted, which, if accurate and not just a rounding artifact in the data, would point to a tight liquidity position. In that case, near‑term access to new capital would be critical to sustaining operations and completing the key clinical trial. As with many small biotechs, the balance sheet strength will likely swing significantly over time depending on capital raises.

Cash Flow

Cash Flow Cash Flow: Cash flow is negative and driven by operating spending on research, clinical work, and corporate expenses. There is essentially no capital spending, so the cash burn is almost entirely tied to running the business and advancing the lead program. Free cash flow has been consistently negative, which is expected at this stage but still important: the company is consuming cash rather than generating it. Without sizable internal cash generation, future progress depends on external funding. The scale of the burn looks relatively modest for a biotech, but given the small asset and cash base, even a modest burn can become a constraint if funding markets are difficult.

Competitive Edge

Competitive Edge Competitive Position: Greenwich LifeSciences is positioned as a focused oncology biotech with a single lead program targeting prevention of breast cancer recurrence in patients who have already completed their main treatment. This “vaccine-like” role in the adjuvant setting is less crowded than the market for treating advanced disease, giving the company a defined niche rather than head‑to‑head competition with every major oncology player. Its competitive story rests heavily on the promising Phase IIb data suggesting strong protection against recurrence and a favorable safety profile. If similar results are confirmed in the large ongoing Phase III trial, that could create a meaningful clinical and marketing advantage. The company is also working to build long‑dated patent protection and has already invested in commercial‑scale manufacturing, which could support a first‑mover edge. However, the company is very small, highly concentrated in one main asset, and operates in a field dominated by large pharma with deep resources. Its competitive position will ultimately depend on Phase III outcomes, regulatory views, real‑world uptake, and its ability to partner or build commercial capabilities at scale.

Innovation and R&D

Innovation and R&D Innovation & R&D: Innovation is the company’s main strength. GLSI‑100 is a peptide‑based immunotherapy designed to train the immune system to recognize HER2‑positive cancer cells and prevent them from returning. This “active immunity” approach is different from standard antibody drugs that directly attack cancer cells; instead, it aims to create long‑lasting immune surveillance after standard treatments are finished. The Phase IIb trial results, with strong signals on recurrence prevention and tolerability, are the scientific foundation of the story. The ongoing Flamingo‑01 Phase III trial is the pivotal test of this innovation. Beyond this core study, management has outlined potential extensions into broader HER2‑expressing populations and even other cancers, suggesting the technology could evolve into a small platform rather than a one‑off product if the science holds. At the same time, virtually all of the company’s value is tied to this R&D program. Trial risk, regulatory risk, and execution risk are all substantial, as is typical with clinical‑stage oncology companies. The R&D strategy is focused and coherent, but also concentrated.

Summary

Summary: Greenwich LifeSciences is a pre‑revenue, clinical‑stage biotech with one central asset that could be practice‑changing if late‑stage results confirm earlier data. Financially, it runs a lean, loss‑making R&D operation with no sales, no debt, and what appears to be a small and potentially tight cash position, making access to new capital a key ongoing consideration. Strategically, the company’s opportunity lies in a clear niche: preventing recurrence in HER2‑positive breast cancer after standard treatment, using an immunotherapy with encouraging early‑stage results and long patent aspirations. Its risks are also clear: heavy dependence on a single program, typical clinical and regulatory uncertainty, and the need to scale or partner in a competitive oncology landscape dominated by much larger players. Overall, this is an early‑stage, high‑uncertainty profile where the scientific potential and the financial fragility are both central to understanding the company’s situation.

NEWS

October 9, 2025 · 6:00 AM UTC

Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial

Read more

October 2, 2025 · 6:00 AM UTC

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium

Read more

September 30, 2025 · 6:00 AM UTC

Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial

Read more

September 18, 2025 · 6:00 AM UTC

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland

Read more

September 10, 2025 · 6:00 AM UTC

Greenwich LifeSciences' GLSI-100 Granted US FDA Fast Track Designation

Read more